OSLO, Norway, Nov. 19, 2019 /PRNewswire/ -- The Board of
Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the
"Company") has on 19th November 2019
resolved to grant Dr Gabriele Elbl,
Vice President Global Regulatory Affairs, 30,000 Performance Share
Units ("PSUs") in connection with her appointment and under the
Company's equity incentive plan that was approved at the Company's
annual general meeting held on 25 April
2019 (the "AGM"). For further information about Dr Elbl
please see the Company's stock exchange announcement on
1 October 2019. Following the
allocation, Dr Elbl holds 30,000 PSUs, 0 options and 0 shares in
Nordic Nanovector.
The Board of Directors of Nordic Nanovector has further resolved
to grant 5,000 PSUs to a new employee under the Company's equity
incentive plan that was approved at the AGM.
In accordance with the resolution at the AGM the PSUs are
secured by a corresponding number of free-standing warrants. The
sole purpose of the free-standing warrants is to ensure delivery of
shares in the Company upon exercise of the PSUs. The free-standing
warrants do not give the PSU-holder a right to subscribe for any
additional shares in the Company.
The terms and conditions of the PSUs, which are part of the
Company's long-term incentive plan for employees, are described on
pages 24-25 in the Company's annual report for 2018.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting radioimmunotherapy
designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly
USD 29 billion by 2026. Nordic
Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in
core markets.
Further information can be found at
www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant
to the Securities Trading Act, Sections 4-2 and 5-12 / Oslo Stock
Exchange's Continuing Obligations, Section 3.2.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--allocation-of-psus,c2967367
View original
content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-allocation-of-psus-300960675.html
SOURCE Nordic Nanovector